Zevra Therapeutics CEO Neil F. McFarlane disposes of 20,000 common shares for USD 224,948

Zevra Therapeutics President and CEO Neil F. McFarlane acquired 50,000 common shares on Oct. 10, 2026 via RSU vesting. McFarlane sold 20,000 common shares on Oct. 12, 2026 at a weighted average price of $11.2474. Directly held common shares totaled 417,225 following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001434647-26-000075), on October 13, 2026, and is solely responsible for the information contained therein. (C)